Influenza, Human  >>  Rapivab (peramivir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rapivab (peramivir) / BioCryst
NCT00419263 / 2006-005196-17: Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

Completed
2
344
US, Canada
Peramivir 150 mg, BCX1812, Peramivir 300 mg, Placebo
BioCryst Pharmaceuticals
Influenza
09/07
09/07
NCT00453999: Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

Completed
2
137
US, Canada, RoW
Peramivir 200 mg, Peramivir 400 mg, Oseltamivir
BioCryst Pharmaceuticals
Influenza
09/08
08/09
NCT00705406: A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

Completed
2
405
US, RoW
Peramivir, Placebo
BioCryst Pharmaceuticals
Acute, Uncomplicated Human Influenza
04/09
10/09
NCT01063933: Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Withdrawn
1/2
0
US
Peramivir
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
08/11
12/12

Download Options